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Trial in the United States, twice the size of the cohort for the
combined US Nurses Health Studies, 12 times bigger than that of
the study of smoking in British doctors,
and 100 times larger than that of the
famous Framingham Heart Study.
Indeed, the driving force behind UK
Biobank is a desire to have adequate
statistical power to study gene–environ-
ment interactions for individual types of
cancer, bearing in mind that, in the UK,
all types of breast cancer combined
account for about 4% of all deaths in
women, and all types of lung cancer
collectively cause about 7% of deaths in men. Despite this, there
is not yet any commitment to go beyond “risk factorology” to
answer questions of public health importance. For example,
Biobank would be an invaluable opportunity to explore the
relationship between individual characteristics and either the
contextual influences on health, such as the physical and social
nature of one’s neighbourhood, or the impact of health and social
policy programs.
Between them, Wellcome, the MRC and the UK Department of
Health have made £61 million available to UK Biobank. But,
1000 days into the project, not a single participant had been
enrolled, even into a pilot study. Instead, time and energy has
been consumed in:
• creating UK Biobank Limited as a private company, limited by
guarantee, and as a registered charity;
• having consortia of universities (mainly their medical schools)
bid to be regional collaborating centres, and then drafting and
redrafting contracts for them to provide “research services” to the
private company;
• recruiting a Chief Executive Officer, a Chief Scientific Officer,
a Chief Operating Officer, a Director of Operations (Laboratory),
a Director of Clinical Operations, a Head of Communications,
and a Chief Information Officer;
• commissioning a market research company to report on
attitudes of people in later middle age to inform a Communica-
tions and Consultation Strategy;
• developing an Ethics and Governance Framework, compli-
ance with which is to be overseen by an Ethics and Governance
Council, whose members will be recommended to the funders by
an appointments committee;
• writing an Intellectual Property and Access Policy; and
• asking a marketing agency to develop a logo and brand.
There have also been protracted debates about which behav-
ioural, lifestyle and environmental factors to document, and
whether the collaborating centres that enrol participants should
have any preferential access to the data and samples held by UK
Biobank, let alone a share in their formal ownership. As yet, there
has been very little consideration as to how endpoints of interest
will be identified and validated. Sir Humphrey Appleby would be
proud!
On the subject of public image, perhaps it is the picture of a
happy granny riding a moped without a helmet, shown in the
original documents with general infor-
mation about the project, that crystal-
lises a suspicion that people with
world-class expertise in the “molecules
of life” do not necessarily have a strong
grasp of public health and the skills
required to enrol and follow up very
large numbers of intact, free-living
humans.
Also interesting is the stark contrast
between UK Biobank and Australia’s
Risk Factor Prevalence Study. The latter was initiated by a non-
government organisation, the National Heart Foundation (NHF),
which succeeded in completing three large, population-based
surveys of risk factors for cardiovascular disease, mainly in
Australia’s capital cities, during the 1980s.1 Enrolment involved
completion of a questionnaire, a brief physical examination,
collection of a blood sample and sometimes a dietary survey,
directly equivalent to what participation in UK Biobank is likely
to involve. The survey centres had their costs covered, as is
proposed for the UK project, but, unlike UK Biobank, their
leaders made up the main committee overseeing the study and
directed the principal analyses and their publication, initially
under the aegis of the NHF alone, and in the last survey in
collaboration with the Australian Institute of Health and Welfare.
Each survey took about a year to plan, a year to complete and
two further years to publish. Covering slightly under 0.1% of
Australia’s population, the Risk Factor Prevalence Study was an
order of magnitude less ambitious than UK Biobank, but it
constitutes a model of energy, trust, efficiency and goodwill that
the Brits are struggling to emulate.
It was not always thus, for Richard Doll and Richard Peto (and
colleagues) recently published the 50-year results from their
study of British doctors, a project whose outstanding achieve-
ments include a follow-up that is 99% complete.2 UK Biobank,
by contrast, seems baffled by its own complexity, stranded in a
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